Carlson Capital L.P. Makes New Investment in CureVac N.V. $CVAC

Carlson Capital L.P. bought a new position in CureVac N.V. (NASDAQ:CVAC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 55,000 shares of the company’s stock, valued at approximately $299,000.

A number of other large investors have also added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd grew its position in CureVac by 354.8% during the second quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company’s stock valued at $30,000 after buying an additional 4,375 shares during the period. Kathmere Capital Management LLC purchased a new position in shares of CureVac during the 2nd quarter worth $60,000. Integrated Wealth Concepts LLC grew its position in shares of CureVac by 25.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock valued at $42,000 after acquiring an additional 3,000 shares during the period. Baron Wealth Management LLC purchased a new stake in shares of CureVac in the 2nd quarter worth $107,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in CureVac by 14.3% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,125 shares of the company’s stock worth $81,000 after purchasing an additional 3,648 shares during the period. Institutional investors own 17.26% of the company’s stock.

CureVac Price Performance

NASDAQ:CVAC opened at $5.48 on Thursday. The business’s 50-day moving average is $5.33 and its 200 day moving average is $5.19. CureVac N.V. has a 12 month low of $2.47 and a 12 month high of $5.72. The company has a market capitalization of $1.23 billion, a P/E ratio of 5.71 and a beta of 2.56. The company has a current ratio of 6.17, a quick ratio of 6.16 and a debt-to-equity ratio of 0.05.

CureVac (NASDAQ:CVAC) last released its quarterly earnings results on Monday, November 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. CureVac had a net margin of 38.21% and a return on equity of 29.57%. The company had revenue of $25.14 million for the quarter, compared to the consensus estimate of $21.40 million. On average, equities research analysts forecast that CureVac N.V. will post 0.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “hold (c-)” rating on shares of CureVac in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $6.83.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.